The Europe diabetic foot ulcer treatment market was valued at USD 1.68 billion in 2024 and is projected to reach USD 2.32 billion by 2030, registering a CAGR of 5.62% from 2025 to 2030. The market expansion is primarily driven by the rising prevalence of diabetic foot ulcers among patients with diabetes, coupled with a growing number of ischemic ulcer cases and diabetic injuries. Furthermore, an aging population prone to chronic wounds and the continuous development of advanced diabetic foot management technologies are strengthening market growth. The increasing burden of diabetes across the continent is also fueling demand for effective and innovative wound care solutions aimed at improving patient outcomes and reducing amputation risks.

The rising incidence of diabetes across Europe directly contributes to the higher prevalence of diabetic foot ulcers. According to the World Health Organization (WHO), diabetes remains one of the most widespread chronic diseases in the European Region, which currently has the highest rate of type 1 diabetes worldwide. By 2045, it is estimated that approximately 1 in 10 individuals in the region will be affected by diabetes. Factors such as sedentary lifestyles, poor dietary patterns, and the rapidly aging population have exacerbated this condition. As the number of diabetic patients increases, so does the risk of complications like neuropathy and peripheral arterial disease, which often lead to the development of foot ulcers, thereby creating a strong demand for specialized wound care and treatment products.

The market is moderately consolidated, featuring a mix of large multinational corporations and emerging players. Leading companies such as Smith & Nephew Plc., ConvaTec Group PLC, and Molnlycke Health Care AB dominate the competitive landscape through their broad product portfolios and strong distribution networks. These key players are heavily investing in research and development to create next-generation therapies, including bioengineered skin substitutes, advanced wound dressings, and regenerative tissue solutions. The continuous introduction of technologically advanced products aimed at accelerating healing, preventing infection, and reducing recurrence rates is expected to enhance the overall efficiency of diabetic foot ulcer management across Europe.

Key Market Trends & Insights:

  • The United Kingdom held a significant share of the market in 2024, supported by its robust healthcare infrastructure and the availability of advanced technologies for diabetic foot ulcer treatment. Meanwhile, Germany is projected to witness notable growth due to the high recurrence rate of foot ulcers among diabetic patients and increasing healthcare expenditure.
  • By Type: The neuro-ischemic ulcer segment accounted for the largest market share of 53.10% in 2023 and is expected to maintain its dominance through 2030, driven by its high prevalence and complex treatment requirements. The neuropathic ulcer segment, however, is projected to grow rapidly due to improved diagnostic capabilities and awareness.
  • By Treatment: The biologics segment led the market with a 36.37% share in 2024, reflecting the growing adoption of bio-based therapies in chronic wound care. The therapy devices segment, including negative pressure wound therapy and oxygen therapy devices, is anticipated to record the fastest CAGR during the forecast period owing to their effectiveness in accelerating healing.
  • By End Use: The homecare segment held a 52.72% share in 2024 and is expected to grow at the fastest rate, driven by the increasing preference for home-based wound management solutions, cost-effectiveness, and greater patient convenience. The availability of portable wound care devices and telemedicine support further encourages this shift toward homecare treatment models.

Order a free sample PDF of the Europe Diabetic Foot Ulcer Treatment Market Intelligence Study, published by Grand View Research.

Key Players

  • ConvaTec Group PLC
  • Acelity L.P. Inc.
  • 3M Health Care
  • Coloplast Corp.
  • Smith & Nephew Plc.
  • Braun SE
  • Medline Industries, LP
  • Organogenesis, Inc.
  • Molnlycke Health Care AB

Recent Developments

  • In October 2024, Molnlycke Health Care AB, a globally recognized leader in the MedTech sector specializing in wound care and management, announced the successful completion of the acquisition of P.G.F. Industry Solutions GmbH. P.G.F. Industry Solutions GmbH is well-known for its Granudacyn product line, specializing in advanced wound cleansing and moistening solutions.
  • In January 2021, Smith & Nephew Plc., a global leader in medical technology, announced the completion of the acquisition of the Extremity Orthopaedics business from Integra LifeSciences Holdings Corporation for USD 240 million. This acquisition strategically aligns with the company’s objective to invest in higher-growth segments, significantly strengthening its extremities business by integrating a dedicated sales channel and a complementary portfolio of shoulder replacement and upper and lower extremities solutions.
  • In January 2020, ConvaTec Group PLC, a prominent global medical technology company, announced the launch of ConvaMax, a new superabsorber dressing distributed by Convatec. The ConvaMax superabsorber wound dressing is designed to effectively manage exuding wounds, including leg ulcers, pressure ulcers, diabetic foot ulcers, and dehisced surgical wounds.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

In conclusion, the Europe diabetic foot ulcer treatment market is poised for steady growth, supported by the increasing prevalence of diabetes and related complications, along with continuous technological advancements in wound care management. The growing adoption of biologics and therapy devices is transforming treatment approaches, improving healing outcomes, and reducing the need for hospitalization. Furthermore, the rising preference for homecare solutions and the integration of advanced medical technologies are enhancing accessibility and convenience for patients. With strong contributions from key players and healthcare infrastructure improvements across major European countries, the market is expected to maintain positive momentum through 2030.